Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday
Phathom Pharmaceuticals (PHAT) is slated to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts projecting a loss of ($0.09) per share. The stock is currently trading down by approximately 6.9%, with significant institutional ownership at 99.01% and a "Moderate Buy" consensus rating from Wall Street analysts. The company, focused on gastrointestinal disease treatments, has an average analyst target price of $20.71.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
Phathom Pharmaceuticals will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, during a live webcast at 8:00 AM EST. The biopharmaceutical company, which focuses on gastrointestinal disease treatments and markets VOQUEZNA® (vonoprazan), will also provide a business update during the event. A recording of the webcast will be available for 90 days on their investor relations website.
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors, who hold a 51% stake in Phathom Pharmaceuticals (NASDAQ:PHAT), experienced an US$88 million decrease in market cap last week, despite a 110% gain over the past year. Frazier Life Sciences Management, LP is the largest shareholder with 16%, and private equity firms hold a 25% stake, influencing the company's board. The article also notes that insiders own approximately US$38 million worth of shares, indicating some alignment with other shareholders.
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors hold a significant majority stake (51%) in Phathom Pharmaceuticals, Inc. While they experienced an US$88m decrease in market cap last week, their long-term gains over the past year (110%) have largely mitigated these recent losses. The article details the ownership breakdown, highlighting that a small number of institutions hold a substantial portion of the company's shares.
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) experienced an US$88 million decrease in market capitalization last week, despite having seen 110% gains over the past year. Institutions hold a significant 51% stake in the company, with the top 9 shareholders collectively owning over half of the shares. While insider ownership is seen as positive, demonstrating alignment, private equity firms also hold a substantial 25% stake.
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Phathom Pharmaceuticals announced that its management team will participate in a fireside chat and one-on-one meetings at the Guggenheim Emerging Outlook Biotech Summit 2026 on February 11-12, 2026, in New York, NY. The company, focused on GI disease treatments, especially vonoprazan products, will host a live webcast of the fireside chat on February 12, 2026, at 11:30 am EST. A recording will be available for 90 days on their investor relations website.
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Phathom Pharmaceuticals, Inc. announced that its management team will participate in a fireside chat and one-on-one meetings at the Guggenheim Emerging Outlook Biotech Summit 2026. The event will take place on February 11-12, 2026, in New York, NY, with the fireside chat scheduled for February 12, 2026, at 11:30 am EST. A live webcast and archived recording will be available on the company's investor relations website.
Phathom Pharmaceuticals sponsors Great GI Debates to showcase GERD treatment
Phathom Pharmaceuticals is sponsoring the 3rd Great GI Debates Conference in Fort Lauderdale, Florida, from February 6-8. The conference will serve as a platform for Phathom to showcase its pioneering GERD treatment and innovative approaches in gastroenterology. This sponsorship underscores Phathom's strategic commitment to advancing digestive health solutions.
(PHAT) Volatility Zones as Tactical Triggers
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is showing weak near and mid-term sentiment, despite a long-term positive outlook. The article presents AI-generated trading strategies including Position Trading, Momentum Breakout, and Risk Hedging, with specific entry, target, and stop-loss zones. These strategies, along with multi-timeframe signal analysis, aim to help traders manage risk and optimize positions for PHAT.
GI treatment developer Phathom joins Guggenheim biotech summit in New York
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in the Guggenheim Emerging Outlook Biotech Summit 2026, with a management team fireside chat scheduled for February 12, 2026, and one-on-one meetings from February 11-12. The biopharmaceutical company, which focuses on GI disease treatments, saw its stock decline by 6.20% on the day this news was published, despite the routine nature of the announcement. Investors can access a live webcast and archived recording of the event on the company's website.
Millennium Management LLC Reduces Stake in Phathom Pharmaceutica
Millennium Management LLC reduced its stake in Phathom Pharmaceuticals Inc. by selling nearly 3 million shares at $16.59 each, reflecting adjustments to its portfolio. Phathom Pharmaceuticals, a clinical-stage biopharmaceutical company, faces financial challenges with negative market performance and low financial strength and profitability ranks. This transaction by a prominent hedge fund highlights concerns about Phathom's financial health, despite its potential in the biotechnology industry.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Analysts
Phathom Pharmaceuticals (NASDAQ:PHAT) has received a consensus "Moderate Buy" recommendation from analysts, with an average 1-year price target of $21.00. The company recently reported better-than-expected quarterly earnings, with an EPS of ($0.15) against a consensus of ($0.30) and revenue of $49.5 million versus an estimated $47.03 million. Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in gastrointestinal diseases, with vonoprazan as its lead asset.
AIGH Capital Management LLC Acquires Shares of 429,000 Phathom Pharmaceuticals, Inc. $PHAT
AIGH Capital Management LLC has acquired 429,000 shares of Phathom Pharmaceuticals (NASDAQ:PHAT) during the third quarter, a new position valued at approximately $5.05 million. This investment represents about 1.4% of AIGH's portfolio and 0.60% ownership of PHAT. Institutional ownership in Phathom Pharmaceuticals is notably high at 99.01%, with several other funds also increasing their stakes, and analysts have a consensus "Moderate Buy" rating with a $21 average price target.
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright analyst Matthew Caufield has reiterated a Buy rating for Phathom Pharmaceuticals (PHAT.US) and maintained a target price of $26. According to TipRanks data, Caufield has a 45.5% success rate and an average return of 10.5% over the past year. This report offers insights into analyst performance based on independent third-party analysis.
Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 By Investing.com
Cantor Fitzgerald has reiterated its Overweight rating and a $29.00 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), indicating an 86% potential upside. This follows a discussion with management where Phathom pre-announced 2025 revenues for its VOQUEZNA therapy are expected to reach $175 million, showing strong revenue growth and gross profit margins. The company also expects to achieve operating profitability in the second half of 2026.
Breakeven On The Horizon For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)
Phathom Pharmaceuticals (NASDAQ:PHAT) is nearing breakeven, with analysts projecting the company to turn profitable in 2027 with a US$93 million profit, after an expected final loss in 2026. This significant turnaround requires an average annual growth rate of 58%. While the company has negative equity, this is often attributed to accumulated prior losses rather than an immediate financial warning.
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability
Phathom Pharmaceuticals reported strong preliminary Q4 and full-year 2025 financial data, with sales exceeding consensus estimates. The company anticipates achieving operating profitability in the second half of 2026 and announced a public offering generating approximately $130 million for general corporate purposes. Voquezna has surpassed one million prescriptions, and a Phase 2 trial for vonoprazan in eosinophilic esophagitis has begun.
Phathom Pharmaceuticals precifica oferta pública de US$ 130 milhões
Phathom Pharmaceuticals (NASDAQ:PHAT) anunciou a precificação de uma oferta pública de 6.875.000 ações ordinárias a US$ 16,00 por ação e 1.250.078 warrants pré-financiados a US$ 15,999 por warrant, totalizando US$ 130 milhões em receita bruta. A empresa pretende usar os recursos para fins corporativos gerais, incluindo capital de giro, comercialização e pesquisa e desenvolvimento, e concedeu aos subscritores uma opção de 30 dias para comprar ações adicionais. A transação deverá ser concluída na sexta-feira.
Latham & Watkins Advises Phathom Pharmaceuticals on US$130 Million Public Offering of Common Stock and Pre-Funded Warrants
Latham & Watkins advised Phathom Pharmaceuticals on its US$130 million public offering. The offering included 6,875,000 shares of common stock at US$16 per share and pre-funded warrants for 1,250,078 shares at US$15.999 each. Phathom also granted underwriters a 30-day option to purchase additional common stock.
Form 424B5 Phathom Pharmaceuticals,
Phathom Pharmaceuticals (NASDAQ: PHAT) is offering 6,875,000 shares of common stock and pre-funded warrants to purchase 1,250,078 shares of common stock at a public offering price of $16.00 per share and $15.999 per pre-funded warrant, aiming to raise approximately $121.7 million in net proceeds. The company, a biopharmaceutical firm focused on GI diseases, intends to use the proceeds for general corporate purposes, including working capital, commercialization, and R&D. Phathom also announced preliminary financial results for Q4 and full year 2025, expecting net revenues of $57-$58 million for Q4 and $174.5-$175.5 million for the full year, and projects achieving operating profitability in the second half of 2026.
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%
Phathom Pharmaceuticals (NASDAQ:PHAT) has seen its stock price increase by 27% in the last thirty days, contributing to a 160% annual gain. The company's high price-to-sales (P/S) ratio of 8.7x is attributed to its strong revenue growth, which significantly outperforms the broader Pharmaceuticals industry. Analysts forecast continued robust revenue growth of 66% annually for the next three years, justifying the high P/S ratio and investor confidence.
Drugmaker developing GI treatments plans new stock and warrant sale
Phathom Pharmaceuticals (PHAT) announced a proposed underwritten public offering of common stock and pre-funded warrants, with proceeds allocated for general corporate purposes including commercialization and R&D. The company also intends to grant underwriters a 30-day option to purchase up to an additional 15% of the offered securities. While the market reacted positively to the news, there is no assurance the offering will be completed.
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Phathom Pharmaceuticals has released its preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company anticipates net revenues of approximately $57M-$58M for Q4 2025 and $174.5M-$175.5M for the full year, and has achieved a major milestone of over one million prescriptions dispensed for its VOQUEZNA products. Phathom also projects achieving operating profitability in the second half of 2026.
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were down on Thursday, with several companies experiencing significant drops in pre-market trading. Immuneering Corp shares fell after announcing updated Phase 2a trial data for its pancreatic cancer drug, while Phathom Pharmaceuticals Inc. declined following a $130 million public offering announcement. Canadian Solar Inc. also saw a decrease after proposing a $200 million public offering.
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has seen its stock soar by 27% in the last thirty days, reaching a 160% annual gain. However, its high price-to-sales (P/S) ratio of 8.7x, significantly above the industry average, might indicate bearish signals. Analysts forecast strong revenue growth of 66% annually over the next three years, outpacing the broader industry's 29% and potentially justifying its elevated P/S ratio.
Phathom Pharmaceuticals Announces Pricing of $130 Million
Phathom Pharmaceuticals has priced its underwritten public offering, expecting to raise approximately $130 million. The offering includes shares of common stock at $16.00 per share and pre-funded warrants at $15.999 per warrant. The proceeds are intended for general corporate purposes, including working capital, commercialization, and research and development expenses.
Phathom Pharmaceuticals announces public offering of common stock By Investing.com
Phathom Pharmaceuticals (NASDAQ:PHAT) has announced a public offering of common stock and pre-funded warrants to fund general corporate purposes, including commercialization and R&D. This comes despite the biopharmaceutical company showing negative free cash flow of $225 million over the past year. The announcement follows a period of positive news for Phathom, including strong Q3 2025 earnings, updated revenue guidance, and favorable analyst ratings from Guggenheim and Raymond James.
Phathom Pharmaceuticals Reports Q4 Preliminary Revenue of $$57 Million to $58 Million
Phathom Pharmaceuticals announced preliminary Q4 revenue projections between $57 million and $58 million. The company also disclosed the pricing of a $130 million public offering of common stock and pre-funded warrants. These financial updates were part of a series of announcements from the biopharmaceutical company focused on gastrointestinal diseases.
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Phathom Pharmaceuticals, Inc. announced its intention to offer and sell shares of its common stock and/or pre-funded warrants in an underwritten public offering, subject to market conditions. The biopharmaceutical company also plans to grant the underwriters a 30-day option for an additional 15% of the securities. Proceeds from the offering are intended for general corporate purposes, including working capital and research and development, with Guggenheim Securities and Cantor acting as joint bookrunning managers.
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Phathom Pharmaceuticals (Nasdaq: PHAT) announced preliminary unaudited financial results for Q4 and full year 2025, expecting net revenues of $57 million to $58 million for Q4 and $174.5 million to $175.5 million for the full year. The company also reported surpassing one million prescriptions for its VOQUEZNA products and anticipates achieving operating profitability in the second half of 2026.
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Phathom Pharmaceuticals announced a proposed underwritten public offering of its common stock and potentially pre-funded warrants, subject to market conditions, with underwriters having a 30-day option for additional purchases. The net proceeds are earmarked for general corporate purposes, including R&D and commercialization efforts. Guggenheim Securities and Cantor are joint bookrunning managers, and the offering is being made under an effective shelf registration statement with the SEC.
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts
Nine research firms currently cover Phathom Pharmaceuticals (NASDAQ:PHAT), giving it a consensus "Moderate Buy" rating with an average one-year price target of $21.00. Institutional investors hold approximately 99.01% of the company's stock. Phathom Pharmaceuticals reported strong Q3 earnings, beating analyst estimates for both EPS and revenue.
Simplify Asset Management Inc. Reduces Position in Phathom Pharmaceuticals, Inc. $PHAT
Simplify Asset Management Inc. significantly reduced its stake in Phathom Pharmaceuticals (NASDAQ:PHAT) by 38.3% in Q3, selling 200,000 shares and now holding 321,935 shares valued at $3.79 million. Despite this, institutional ownership of PHAT remains high at 99.01%, with other major institutions like Frazier Life Sciences and Invesco Ltd. increasing their positions. Phathom Pharmaceuticals also reported better-than-expected Q3 earnings and revenue, and analysts maintain a "Moderate Buy" rating with a consensus price target of $21.00.
Ações da Phathom Pharmaceuticals atingem máxima de 52 semanas a US$ 17,87
As ações da Phathom Pharmaceuticals Inc. alcançaram uma máxima de 52 semanas de US$ 17,87, refletindo um crescimento de 130,35% em um ano. Este marco é impulsionado por resultados financeiros impressionantes no terceiro trimestre de 2025, com receita do Voquezna de US$ 49,5 milhões e projeção anual elevada para US$ 170-175 milhões. Analistas da Guggenheim e Raymond James mantiveram ou iniciaram recomendações de compra, destacando o potencial do Voquezna, que também está em ensaios de Fase 2 para esofagite eosinofílica.
Phathom Pharmaceuticals stock hits 52-week high at $17.87
Phathom Pharmaceuticals (PHAT) stock has reached a 52-week high of $17.87, reflecting a 130.35% increase over the past year and indicating growing investor confidence. The company also reported strong Q3 2025 earnings for Voquezna and initiated a Phase 2 trial for its use in eosinophilic esophagitis, leading analysts to raise their price targets.
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year High - What's Next?
Phathom Pharmaceuticals (NASDAQ:PHAT) hit a new 52-week high of $16.60, with shares up approximately 3.6% during Thursday's trading. The company reported beating Q3 earnings estimates, and analysts have a "Moderate Buy" consensus rating with a $21.00 average price target. Despite strong institutional ownership, Phathom remains unprofitable with expected negative EPS for the current year.
Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Earnings Haven't Escaped The Attention Of Investors
Phathom Pharmaceuticals (NASDAQ:PHAT) boasts a high price-to-sales (P/S) ratio of 7.2x, significantly above the pharmaceutical industry average, which suggests investor optimism. This elevated P/S ratio is driven by strong revenue growth and analyst forecasts predicting 66% annual revenue growth over the next three years, substantially outperforming the broader industry. While a high P/S can indicate overvaluation, in Phathom's case, it reflects market confidence in its future revenue potential.
Assessing Phathom Pharmaceuticals (PHAT) Valuation After Bullish Rating, Earnings Beat, Raised Guidance and VOQUEZNA Trial Progress
Phathom Pharmaceuticals (PHAT) is gaining significant investor attention due to a bullish analyst rating, better-than-expected quarterly earnings, an increased revenue forecast for 2025, and advancements in its VOQUEZNA clinical trials. Despite its shares more than doubling this year, the company still trades at a substantial discount to analyst targets, with a fair value estimated at $22.90 against a $15.24 last close, suggesting potential for further upside if growth assumptions hold. However, risks such as reimbursement challenges or trial setbacks for VOQUEZNA could impact its growth trajectory.
Does Earnings Beat And Voquezna Expansion Change The Bull Case For Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals (PHAT) recently received a "Strong Buy" rating after exceeding Q3 2025 forecasts, raising revenue guidance, and advancing Voquezna for GERD. The company is also expanding Voquezna into new indications like eosinophilic esophagitis, further diversifying its gastrointestinal franchise. While these developments strengthen the near-term commercialization story, the primary investment thesis remains Voquezna's ability to drive profitability and offset cash burn before generic competition arrives.
Raymond James Financial Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT)
Raymond James Financial has initiated coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a "strong-buy" rating and a $28 price target, indicating a 92% upside. Analyst consensus for PHAT is a "Moderate Buy" with an average target of $21, reflecting a range of views from various firms. The company reported strong institutional ownership, favorable quarterly earnings, and significant revenue, with recent buys by Millennium Management and Frazier Life Sciences.
Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating
Raymond James has initiated coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a "Strong Buy" rating and a price target of $28, indicating a 92% upside. The firm highlighted Phathom's FDA-approved GERD treatment, Voquezna, and its strong commercial strategy, noting its attractive long-term valuation risk/reward profile. This initiation follows Phathom's impressive Q3 2025 earnings and the launch of a Phase 2 clinical trial for Voquezna in eosinophilic esophagitis.
Frazier Life Sciences Management L.P. Purchases 2,357,210 Shares of Phathom Pharmaceuticals, Inc. $PHAT
Frazier Life Sciences Management L.P. has significantly increased its stake in Phathom Pharmaceuticals (PHAT) by 23.3%, acquiring an additional 2,357,210 shares. This transaction brings their total holdings to 12,466,489 shares, representing about 17.57% of the company and making it their 6th largest holding. The move follows Phathom's strong quarterly earnings, which surpassed analyst expectations in both EPS and revenue.
683 Capital Management LLC Grows Stock Position in Phathom Pharmaceuticals, Inc. $PHAT
683 Capital Management LLC significantly increased its stake in Phathom Pharmaceuticals (NASDAQ:PHAT) by 45.7% in Q2, bringing its total to 2,105,000 shares valued at $20.19 million, making it the 11th largest holding in its portfolio. Phathom Pharmaceuticals has a consensus "Moderate Buy" rating from analysts with an average price target of $21.00, and recently reported better-than-expected quarterly earnings and revenue. The stock currently trades around $14.56 with a market cap of $1.04 billion.
Phathom Pharmaceuticals stock hits 52-week high at $16.27
Phathom Pharmaceuticals (PHAT) stock reached a 52-week high of $16.27, reflecting an 82.47% surge over the past year and significant investor confidence in its growth potential. The company's impressive gross profit margins and healthy current ratio underpin this rise, despite trading near its Fair Value. Recent positive news includes exceeding Q3 2025 earnings estimates, a raised price target from Guggenheim, new revenue guidance, and the initiation of a Phase 2 trial for Voquezna in eosinophilic esophagitis.
Phathom Pharmaceuticals stock hits 52-week high at $16.27
Phathom Pharmaceuticals (PHAT) stock reached a 52-week high of $16.27, marking an 82.47% increase over the past year and reflecting significant investor confidence. The company reported strong third-quarter 2025 earnings, exceeding revenue and EPS expectations, and analysts have raised price targets. Phathom is also expanding its clinical development with a Phase 2 trial for Voquezna in eosinophilic esophagitis.
(PHAT) and the Role of Price-Sensitive Allocations
This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), identifying weak near-term sentiment but strong long-term potential. An exceptional 77.5:1 risk-reward setup is highlighted, targeting a 22.9% gain versus 0.3% risk. The analysis includes institutional trading strategies tailored for different risk profiles (position, momentum breakout, and risk hedging) and multi-timeframe signal analysis.
Barclays Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Equal-Weight Recommendation
Barclays has initiated coverage of Phathom Pharmaceuticals (PHAT) with an Equal-Weight recommendation, as reported by Fintel. Analysts project a 54.03% upside for the stock, with an average one-year price target of $22.95 per share. Institutional ownership data indicates a bullish outlook for PHAT, with 264 funds holding positions and a put/call ratio of 0.03.
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD
Phathom Pharmaceuticals (PHAT) stock recently reached a 52-week high of $16.08, marking an impressive 79.93% increase over the past year and a 271.81% surge in six months. This growth is driven by positive pipeline developments, strategic initiatives, and strong financial fundamentals, including an 87.25% gross profit margin. Despite not yet being profitable, InvestingPro analysis suggests the company is slightly undervalued, highlighting investor confidence in its future in the competitive healthcare sector.
Phathom Pharmaceuticals Publishes Positive Phase 3 Trial Results for VOQUEZNA® in Treating Nighttime GERD Symptoms
Phathom Pharmaceuticals announced positive Phase 3 trial results for its drug VOQUEZNA (vonoprazan) in treating nighttime GERD symptoms. The study, published in the American Journal of Gastroenterology, showed VOQUEZNA provided rapid and sustained relief, significantly improving heartburn-free nights and sleep quality for patients with Non-Erosive Reflux Disease (NERD). The medication was generally well-tolerated, highlighting its potential to address an unmet need in GERD treatment.
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom Pharmaceuticals has announced the dosing of the first patient in its Phase 2 pHalcon-EoE-201 clinical trial, evaluating VOQUEZNA (vonoprazan) tablets for the treatment of eosinophilic esophagitis (EoE) in adults. Topline results from this randomized, double-blind, placebo-controlled study are expected in 2027. This trial aims to address the significant unmet needs in EoE treatment and could potentially support a pediatric program, strengthening VOQUEZNA's regulatory exclusivity.
